MedTrace Logo

Weight Loss Management in Endometrial Cancer Survivors

NCT06877572 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2025-10-27

No results posted yet for this study

Summary

This study is being done to understand how oncologists can engage a multidisciplinary team to help endometrial cancer survivors with obesity to engage in a weight management program and potentially start a weight loss medication. Obesity often impacts the future health and longevity of early-stage endometrial cancer survivors more than their cancer diagnosis.

Patients will be referred to the KUMC OB/Gyn weight management clinic to discuss weight management options.

* If patients decide to use medications for weight loss, then the study will collect data from their chart that is recorded as part of routine monitoring for patients on weight loss medications.
* If patients decide not to use any medications, the study will monitor physical exam and lab data collected as part of their routine medical care.

The study will also try to understand reasons why patients did or did not start using a weight loss medication.

Conditions

Interventions

BEHAVIORAL

Weight loss with pharmacotherapy

Patients will meet with a weight management specialist and discuss their options for weight loss including medications (GLP-1 agonist, naltrexone/bupropion, orlistat, or phentermine/topiramate) or bariatric surgery.

BEHAVIORAL

Weight loss without pharmacotherapy

Participants not on medications will have their weight recorded at subsequent cancer surveillance or other routine medical visits

Sponsors & Collaborators

  • University of Kansas Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-25
Primary Completion
2028-10-31
Completion
2030-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06877572 on ClinicalTrials.gov